Research ArticleEvidence-Based Clinical Medicine

The Symptom Cluster-Based Approach to Individualize Patient-Centered Treatment for Major Depression

Steven Y. Lin and Michael B. Stevens
The Journal of the American Board of Family Medicine January 2014, 27 (1) 151-159; DOI: https://doi.org/10.3122/jabfm.2014.01.130145

References

  1. 1.↵
    1. Kessler RC,
    2. Berglund P,
    3. Demler O,
    4. et al
    . Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Kessler RC,
    2. Berglund P,
    3. Demler O,
    4. et al
    ; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095–105.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Wang PS,
    2. Lane M,
    3. Olfson M,
    4. Pincus HA,
    5. Wells KB,
    6. Kessler RC
    . Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:629–40.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Agency for Health Care Policy and Research. Depression Guideline Panel, Vol 2: treatment of major depression, clinical practice guideline, no 5. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Dept of Health and Human Services; 1993.
  5. 5.↵
    American Psychiatric Association. Practice guideline for treatment of patients with major depressive disorder. 2nd ed. Washington, DC: American Psychiatric Association Press; 2000.
  6. 6.↵
    1. Qaseem A,
    2. Snow V,
    3. Denberg TD,
    4. Forciea MA,
    5. Owens DK
    ; Clinical Efficacy Assessment Subcommittee of American College of Physicians. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725–33.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Greenberg PE,
    2. Kessler RC,
    3. Birnbaum HG,
    4. et al
    . The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465–75.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Montano CB
    . Recognition and treatment of depression in a primary care setting. J Clin Psychiatry 1994;55:18–34.
    OpenUrl
  9. 9.↵
    1. Mojtabai R
    . Americans' attitudes toward mental health treatment seeking: 1990–2003. Psychiatr Serv 2007;58:642–51.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Kessler RC,
    2. Demler O,
    3. Frank RG,
    4. et al
    . Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352:2515–23.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Cunningham PJ
    . Beyond parity: primary care physicians' perspectives on access to mental health care. Health Aff (Millwood) 2009;28:w490–501.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Olfson M,
    2. Marcus SC
    . National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848–56.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Mark TL,
    2. Levit KR,
    3. Buck JA
    . Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv 2009;60:1167.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Cherry DK,
    2. Woodwell DA,
    3. Rechtsteiner EA
    . National Ambulatory Medical Care Survey: 2005 summary. Advance Data From Vital and Health Statistics; No. 387. Hyattsville, MD: National Center for Health Statistics; 2007.
  15. 15.↵
    1. Middelton K,
    2. Him E,
    3. Xu J
    . National Hospital Ambulatory Medical Care Survey: 2005 Outpatient Department Summary. Adv Data 2007;(389):1–34.
  16. 16.↵
    1. Cipriani A,
    2. Purgato M,
    3. Furukawa TA,
    4. et al
    . Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012;(7):CD006534.
  17. 17.↵
    1. Cipriani A,
    2. Santilli C,
    3. Furukawa TA,
    4. et al
    . Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;(2):CD006532.
  18. 18.↵
    1. Cipriani A,
    2. Brambilla P,
    3. Furukawa T,
    4. et al
    . Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005;(4):CD004185.
  19. 19.↵
    1. Omori IM,
    2. Watanabe N,
    3. Nakagawa A,
    4. et al
    . Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2010;(3):CD006114.
  20. 20.↵
    1. Katzman MA,
    2. Tricco AC,
    3. McIntosh D,
    4. et al
    . Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. J Clin Psychiatry 2007;68:1845–59.
    OpenUrlPubMedWeb of Science
  21. 21.↵
    1. Cipriani A,
    2. La Ferla T,
    3. Furukawa TA,
    4. et al
    . Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010;(4):CD006117.
  22. 22.↵
    1. Thase ME,
    2. Kornstein SG,
    3. Germain JM,
    4. Jiang Q,
    5. Guico-Pabia C,
    6. Ninan PT
    . An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144–54.
    OpenUrlPubMed
  23. 23.↵
    1. Cipriani A,
    2. Koesters M,
    3. Furukawa TA,
    4. et al
    . Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012;(10):CD006533.
  24. 24.↵
    1. Nakagawa A,
    2. Watanabe N,
    3. Omori IM,
    4. et al
    . Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;(3):CD006529.
  25. 25.↵
    1. Smith D,
    2. Dempster C,
    3. Glanville J,
    4. Freemantle N,
    5. Anderson I
    . Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396–404.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Dhillon S,
    2. Yang LP,
    3. Curran MP
    . Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008;68:653–89.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Watanabe N,
    2. Omori IM,
    3. Nakagawa A,
    4. et al
    . Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011;(12):CD006528.
  28. 28.↵
    1. Watanabe N,
    2. Omori IM,
    3. Nakagawa A,
    4. et al
    ; Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. J Clin Psychiatry 2008;69:1404–15.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Thase ME
    . Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60:28–31.
    OpenUrlPubMed
  30. 30.↵
    1. Laughren TP,
    2. Gobburu J,
    3. Temple RJ,
    4. et al
    . Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011;72:1166–73.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Guaiana G,
    2. Barbui C,
    3. Hotopf M
    . Amitriptyline for depression. Cochrane Database Syst Rev 2007;(3):CD004186.
  32. 32.↵
    1. Mottram P,
    2. Wilson K,
    3. Strobl J
    . Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;(1):CD003491.
  33. 33.↵
    1. Fekadu A,
    2. Rane LJ,
    3. Wooderson SC,
    4. Markopoulou K,
    5. Poon L,
    6. Cleare AJ
    . Prediction of longer-term outcome of treatment-resistant depression in tertiary care. Br J Psychiatry 2012;201:369–75.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Stahl SM
    . Essential psychopharmacology: neuroscientific basis and practical applications. 2nd ed. Cambridge, UK: Cambridge University Press; 2000.
  35. 35.↵
    1. Hansen RA,
    2. Gartlehner G,
    3. Lohr KN,
    4. Gaynes BN,
    5. Carey TS
    . Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415–26.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Gartlehner G,
    2. Hansen RA,
    3. Thieda P,
    4. et al
    . Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Rockville, MD: Agency for Healthcare Research and Quality, US Dept of Health and Human Services; 2007.
  37. 37.↵
    1. Gartlehner G,
    2. Gaynes BN,
    3. Hansen RA,
    4. et al
    . Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734–50.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Cipriani A,
    2. Furukawa TA,
    3. Salanti G,
    4. et al
    . Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Cipriani A,
    2. Furukawa TA,
    3. Geddes JR,
    4. et al
    ; MANGA Study Group. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. J Clin Psychiatry 2008;69:1732–42.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Gartlehner G,
    2. Hansen RA,
    3. Morgan LC,
    4. et al
    . Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Ann Intern Med 2011;155:772–85.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Gartlehner G,
    2. Hansen RA,
    3. Morgan LC,
    4. et al
    . Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality, US Dept of Health and Human Services; 2011.
  42. 42.↵
    1. Arroll B,
    2. Elley CR,
    3. Fishman T,
    4. et al
    . Antidepressants versus placebo for depression in primary care. Cochrane Database Syst Rev 2009;(3):CD007954.
  43. 43.↵
    1. Gartlehner G,
    2. Gaynes BN,
    3. Hansen RA,
    4. Lohr KN
    . Ranking antidepressants. Lancet 2009;373:1761.
    OpenUrlPubMedWeb of Science
  44. 44.↵
    1. Jefferson T
    . Ranking antidepressants. Lancet 2009;373:1759.
    OpenUrlPubMedWeb of Science
  45. 45.↵
    1. Ioannidis JP
    . Ranking antidepressants. Lancet 2009;373:1759–60.
    OpenUrlPubMedWeb of Science
  46. 46.↵
    1. Seyringer ME,
    2. Kasper S
    . Ranking antidepressants. Lancet 2009;373:1760–1.
    OpenUrlPubMedWeb of Science
  47. 47.↵
    1. Turner E,
    2. Moreno SG,
    3. Sutton AJ
    . Ranking antidepressants. Lancet 2009;373:1760.
    OpenUrlPubMedWeb of Science
  48. 48.↵
    1. Schwan S,
    2. Hallberg P
    . Ranking antidepressants. Lancet 2009;373:1761.
    OpenUrlPubMedWeb of Science
  49. 49.↵
    1. Gartlehner G,
    2. Thaler K,
    3. Hill S,
    4. Hansen RA
    . How should primary care doctors select which antidepressants to administer? Curr Psychiatry Rep 2012;14:360–9.
    OpenUrlPubMed
  50. 50.↵
    1. Zimmerman M,
    2. Posternak M,
    3. Friedman M,
    4. et al
    . Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry 2004;161:1285–9.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Kim HM,
    2. Zivin K,
    3. Ganoczy D,
    4. et al
    . Predictors of alternative antidepressant agent initiation among U.S. veterans diagnosed with depression. Pharmacoepidemiol Drug Saf 2010;19:1049–56.
    OpenUrlPubMed
  52. 52.↵
    1. Garrison GD,
    2. Levin GM
    . Factors affecting prescribing of the newer antidepressants. Ann Pharmacother 2000;34:10–4.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Thaler KJ,
    2. Morgan LC,
    3. Van Noord M,
    4. et al
    . Comparative effectiveness of second-generation antidepressants for accompanying anxiety, insomnia, and pain in depressed patients: a systematic review. Depress Anxiety 2012;29:495–505.
    OpenUrlPubMed
  54. 54.↵
    1. Gaynes BN,
    2. Farley JF,
    3. Dusetzina SB,
    4. et al
    . Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? Depress Anxiety 2011;28:989–98.
    OpenUrlPubMed
  55. 55.↵
    1. Ozdemir E,
    2. Gursoy S,
    3. Bagcivan I
    . The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats. J Physiol Sci 2012;62:317–23.
    OpenUrlPubMed
  56. 56.↵
    National Collaborating Centre for Mental Health. Post-traumatic stress disorder (PTSD): the management of PTSD in adults and children in primary and secondary care. London: National Institute for Clinical Excellence; 2005.
  57. 57.↵
    Wikipedia. Nefazodone. Updated November 3, 2013. Available from: http://en.wikipedia.org/wiki/Nefazodone. Accessed November 8, 2013.
  58. 58.↵
    1. Moore RA,
    2. Derry S,
    3. Aldington D,
    4. Cole P,
    5. Wiffen PJ
    . Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;(12):CD008242.
  59. 59.↵
    1. Goldenberg DL,
    2. Burckhardt C,
    3. Crofford L
    . Management of fibromyalgia syndrome. JAMA 2004;292:2388–95.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Bril V,
    2. England J,
    3. Franklin GM,
    4. et al
    ; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R 2011;3:345–52.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Loder E,
    2. Burch R,
    3. Rizzoli P
    . The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 2012;52:930–45.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010;112:810–33.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Barbui C,
    2. Hotopf M
    . Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Br J Psychiatry 2001;178:129–44.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    1. Yonkers KA,
    2. Wisner KL,
    3. Stewart DE,
    4. et al
    . The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403–13.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    1. Stewart DE
    . Clinical practice. Depression during pregnancy. N Engl J Med 2011;365:1605–11.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Hetrick SE,
    2. McKenzie JE,
    3. Cox GR,
    4. Simmons MB,
    5. Merry SN
    . Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012;(11):CD004851.
  67. 67.↵
    1. Hetrick S,
    2. Merry S,
    3. McKenzie J,
    4. Sindahl P,
    5. Proctor M
    . Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2007;(3):CD004851.
  68. 68.↵
    Consumer Reports Health Best Buy Drugs. Antidepressants: summary of recommendations. September 2011. Available from: http://www.consumerreports.org/health/best-buy-drugs/antidepressants.htm. Accessed November 8, 2013.
  69. 69.↵
    1. Ramsberg J,
    2. Asseburg C,
    3. Henriksson M
    . Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7:e42003.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Ruhé HG,
    2. Huyser J,
    3. Swinkels JA,
    4. Schene AH
    . Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006;67:1836–55.
    OpenUrlPubMedWeb of Science
  71. 71.↵
    1. Papakostas GI
    . Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009;70:16–25.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Connolly KR,
    2. Thase ME
    . If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71:43–64.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords